Alexion pays $1.4B for Bay Area biotech in bid to double commercial portfolio

With its own product portfolio under pressure, Alexion Pharmaceuticals is working to solidify its foothold in the red-hot blood disorder market through a $1.4 billion acquisition.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.